# UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON D.C. 20549

# FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): August 6, 2024



### Ascent Industries Co.

(Exact name of registrant as specified in its charter) 0-19687

57-0426694

Delaware

1400 16th Street, Suite 270, Oak Brook, Illinois 60523	
(Address of principal executive offices) (Zip Code)	
(630) 884-9181	
(Registrant's telephone number, including area code)	
Inapplicable	
(Former name or former address if changed since last report)	
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provision General Instruction A.2. below):	s (see
<ul> <li>□ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</li> <li>□ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</li> <li>□ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</li> <li>□ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</li> </ul>	
Securities registered pursuant to Section 12(b) of the Act:	
<u>Title of each class</u> <u>Trading Symbol</u> <u>Name of exchange on which registered</u>	
Common Stock, par value \$1.00 per share ACNT NASDAQ Global Market	
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405 of this chapter) 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2 of this chapter).  Emerging growth company □  If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised accounting standards provided pursuant to Section 13(a) of the Exchange Act. □	

### Item 2.02. Results of Operations and Financial Condition

On August 6, 2024, Ascent Industries Co. ("the Company") issued a press release announcing financial information for its second quarter ended June 30, 2024. The press release is attached as Exhibit 99.1 to this Form 8-K and is furnished to, but not filed with, the Commission.

# Item 9.01. Financial Statements and Exhibits

(d) Exhibits

<u>Exhibit Number</u> <u>Description of Exhibit</u>

99.1 Ascent Industries Co. Press Release dated August 6, 2024

104 Cover Page Interactive Data File (embedded within the Inline XBRL document)

# SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on behalf by the undersigned hereunto duly authorized.

Dated: August 6, 2024

Ascent Industries Co.

By: /s/ Ryan Kavalauskas

Ryan Kavalauskas Chief Financial Officer



# **Ascent Industries Reports Second Quarter 2024 Results**

Oak Brook, Illinois, August 6, 2024 – Ascent Industries Co. (Nasdaq: ACNT) ("Ascent" or the "Company"), an industrials company focused on the production of specialty chemicals and industrial tubular products, is reporting its results for the second quarter ended June 30, 2024.

#### Second Quarter 2024 Summary<sup>1</sup>

(in millions, except per share and margin)	Q2 2024	Q2 2023	Change
Net Sales	\$50.2	\$50.4	(0.3)%
Gross Profit	\$5.9	\$(0.8)	854.2%
Gross Profit Margin	11.7%	(1.5)%	1320bps
Net Loss	\$(0.2)	\$(6.1)	96.8%
Diluted Loss per Share	\$(0.02)	\$(0.60)	96.7%
Adjusted EBITDA	\$2.1	\$(4.8)	144.1%
Adjusted EBITDA Margin	4.2%	(9.4)%	1360bps

<sup>&</sup>lt;sup>1</sup>On December 22, 2023, the Company closed on a transaction to sell substantially all of the assets of Specialty Pipe & Tube ("SPT"). As a result, financial results from SPT have been categorized into discontinued operations.

#### **Management Commentary**

"Our stabilization efforts and aggressive self-help have started to yield tangible results in Q2 2024, despite continued soft market conditions," said Ascent CEO Bryan Kitchen. "Our relentless efforts to reduce costs, improve strategic sourcing and optimize our product mix have led to a significant year-over-year improvement in adjusted EBITDA and bottom-line results, while also right-sizing the organization for long-term growth.

"It has been our goal to create a more predictable, reliable, and profitable operating model, and I am proud that we are beginning to deliver on that goal. Momentum is building, and we are optimistic about our ability to achieve incremental financial improvements throughout the year while enhancing the quality of our business development pipeline. With a healthy balance sheet and no outstanding debt, we continue to build the foundation for long-term growth. Our actions are positioning Ascent to fully execute our growth strategy, delivering durable value for our shareholders."

# Second Quarter 2024 Financial Results

Net sales from continuing operations were \$50.2 million compared to \$50.4 million in the second quarter of 2023. The slight decline is primarily attributable to a decrease in pricing partially offset by an increase in volume across both segments.

Gross profit from continuing operations increased to \$5.9 million, or 11.7% of net sales, compared to \$(0.8) million, or (1.5)% of net sales, in the second quarter of 2023. The increase was primarily attributable to continued cost and product mix optimization initiatives leading to cost improvements across both segments.

Net loss from continuing operations improved to \$(0.2) million, or \$(0.02) diluted loss per share, compared to net loss from continuing operations of \$(6.1) million, or \$(0.60) diluted loss per share, in the second quarter of 2023. The improvement was primarily attributable to the aforementioned increase in gross profit and a year-over-year decrease in interest expense due to lower debt outstanding.

Adjusted EBITDA increased to \$2.1 million compared to \$(4.8) million in the second quarter of 2023, with adjusted EBITDA margin increasing significantly to 4.2% compared to (9.4)% in the prior year period. The improvement was primarily driven by the aforementioned cost and product mix optimization initiatives.

#### Segment Results

Ascent Chemicals – net sales in the second quarter of 2024 increased slightly to \$21.5 million compared to \$21.4 million in the second quarter of 2023. Operating income in the second quarter improved to \$0.4 million compared to operating loss of \$0.8 million in the prior year period. Adjusted EBITDA in the second quarter increased significantly to \$1.7 million compared to \$0.3 million in the prior year period. As a percentage of segment net sales, adjusted EBITDA increased significantly to 7.9% compared to 1.5% in the second quarter of 2023.

Ascent Tubular – net sales from continuing operations in the second quarter of 2024 were \$28.7 million compared to \$29.0 million in the second quarter of 2023. Operating income from continuing operations in the second quarter increased to \$0.9 million compared to operating loss from continuing operations of \$3.3 million in the prior year period. Adjusted EBITDA from continuing operations in the second quarter increased significantly to \$1.7 million compared to \$(2.5) million in the prior year period. As a percentage of segment net sales, adjusted EBITDA was 5.9% compared to (8.5)% in the second quarter of 2023.

### **Liquidit**v

As of June 30, 2024, the Company had no debt outstanding under its revolving credit facilities and had \$62.7 million in availability under its revolving credit facility.

For the quarter ended June 30, 2024, the Company repurchased 15,233 shares at an average cost of \$10.25 per share for approximately \$0.2 million.

#### **Conference Call**

Ascent will conduct a conference call today at 5:00 p.m. Eastern time to discuss its results for the second quarter ended June 30, 2024.

Ascent management will host the conference call, followed by a question-and-answer period.

Date: Tuesday, August 6, 2024 Time: 5:00 p.m. Eastern time Live Call Registration Link: <u>Here</u> Webcast Registration Link: <u>Here</u>

To access the call by phone, please register via the live call registration link above or here and you will be provided with dial-in instructions and details. If you have any difficulty connecting with the conference call, please contact Gateway Group at 1-949-574-3860.

The conference call will also be broadcast live and available for replay via the webcast registration link above othere. The webcast will be archived for one year in the investor relations section of the Company's website at <a href="https://www.ascentco.com">www.ascentco.com</a>.

#### **About Ascent Industries Co.**

Ascent Industries Co. (Nasdaq: ACNT) is a company that engages in a number of diverse business activities including the production of specialty chemicals and industrial tubular products. For more information about Ascent, please visit its website at <a href="https://www.ascentco.com">www.ascentco.com</a>.

# Forward-Looking Statements

This press release may include "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 and other applicable federal securities laws. All statements that are not historical facts are forward-looking statements. Forward looking statements can be identified through the use of words such as "estimate," "project," "intend," "expect," "believe," "should," "anticipate," "hope," "optimistic," "plan," "outlook," "should," "could," "may" and similar expressions. The forward-looking statements are subject to certain risks and uncertainties which could cause actual results to differ materially from historical results or those anticipated. Readers are cautioned not to place undue reliance on these forward-looking statements and to review the risks as set forth in more detail in Ascent Industries Co.'s Securities and Exchange Commission filings, including our Annual Report on Form 10-K, which filings are available from the SEC or on our website. Ascent Industries Co. assumes no obligation to update any forward-looking information included in this release.

#### **Non-GAAP Financial Information**

Financial statement information included in this earnings release includes non-GAAP (Generally Accepted Accounting Principles) measures and should be read along with the accompanying tables which provide a reconciliation of non-GAAP measures to GAAP measures.

Adjusted EBITDA is a non-GAAP financial measure that the Company believes is useful to investors in evaluating its results to determine the value of a company. An item is excluded in the measure if its periodic value is inconsistent and sufficiently material that not identifying the item would render period comparability less meaningful to the reader or if including the item provides a clearer representation of normalized periodic earnings. The Company excludes in Adjusted EBITDA two categories of items: 1) Base EBITDA components, including: interest expense, income taxes, depreciation and amortization, and 2) Material transaction costs including: goodwill impairment, asset impairment, gain on lease modification, stock-based compensation, non-cash lease cost, acquisition costs and other fees, shelf registration costs, loss on extinguishment of debt, retention costs and restructuring & severance costs from net income.

Management believes that these non-GAAP measures are useful because they are key measures used by our management team to evaluate our operating performance, generate future operating plans and make strategic decisions as well as allow readers to compare the financial results between periods. Non-GAAP measures should not be considered as an alternative to any measure of performance or financial condition as promulgated under GAAP, and investors should consider the Company's performance and financial condition as reported under GAAP and all other relevant information when assessing the performance or financial condition of the Company. Non-GAAP measures have limitations as analytical tools, and investors should not consider them in isolation or as a substitute for analysis of the Company's results or financial condition as reported under GAAP

### **Company Contact**

Ryan Kavalauskas Chief Financial Officer 1-630-884-9181

#### **Investor Relations**

Cody Slach and Cody Cree Gateway Group, Inc. 1-949-574-3860 ACNT@gateway-grp.com

Assets Current assets: Cash and cash equivalents Accounts receivable, net of allowance for credit losses of \$808 and \$463, respectively Inventories Prepaid expenses and other current assets Assets held for sale	\$	3,595 30,154	\$ December 31, 2023
Cash and cash equivalents Accounts receivable, net of allowance for credit losses of \$808 and \$463, respectively Inventories Prepaid expenses and other current assets	\$	30,154	\$
Accounts receivable, net of allowance for credit losses of \$808 and \$463, respectively  Inventories  Prepaid expenses and other current assets	\$	30,154	\$
Inventories Prepaid expenses and other current assets			1,851
Prepaid expenses and other current assets			26,604
		45,917	52,306
Assets held for sale		3,988	4,879
		1,259	2,912
Current assets of discontinued operations		65	861
Total current assets		84,978	89,413
Property, plant and equipment, net		27,643	29,755
Right-of-use assets, operating leases, net		27,073	27,784
Intangible assets, net		7,752	8,496
Deferred income taxes		7,663	5,808
Deferred charges, net		54	104
Other non-current assets, net		3,075	1,935
Total assets	\$	158,238	\$ 163,295
Liabilities and Shareholders' Equity			
Current liabilities:			
Accounts payable	\$	16,790	\$ 16,416
Accrued expenses and other current liabilities		6,472	5,108
Current portion of note payable		914	360
Current portion of operating lease liabilities		1,194	1,140
Current portion of finance lease liabilities		286	292
Current liabilities of discontinued operations		1,213	1,473
Total current liabilities	-	26,869	24,789
Long-term portion of operating lease liabilities		29,110	29,729
Long-term portion of finance lease liabilities		1,163	1,307
Other long-term liabilities		54	60
Total non-current liabilities	-	30,327	31,096
Total liabilities	\$	57,196	\$ 55,885
Commitments and contingencies			
Shareholders' equity:			
Common stock, par value \$1 per share; 24,000,000 shares authorized; 11,085,103 and 10,124,737 shares issued and outstanding, respectively	\$	11,085	\$ 11,085
Capital in excess of par value		47,111	47,333
Retained earnings		52,098	58,517
	-	110,294	116,935
Less: cost of common stock in treasury - 960,366 and 990,282 shares, respectively		(9,252)	(9,525)
Total shareholders' equity		101,042	107,410
Total liabilities and shareholders' equity	\$	158,238	\$ 163,295

Note: The condensed consolidated balance sheets at December 31, 2023 have been derived from the audited consolidated financial statements at that date.

		Three Months Ended June 30,			Six Months Ended June 30,			
		2024		2023		2024		2023
Net sales								
Tubular Products	\$	28,721	\$	28,992	\$	52,536	\$	60,053
Specialty Chemicals		21,468		21,363		41,764		45,112
All Other			_					50
		50,189		50,355		94,300		105,215
Operating income (loss) from continuing operations		_				_		
Tubular Products		889		(3,302)		(613)		(6,596
Specialty Chemicals		429		(806)		(1,010)		546
All Other		(100)		(74)		(261)		(552
Corporate								
Unallocated corporate expenses		(1,429)		(2,750)		(3,579)		(6,455
Acquisition costs and other		(52)		(17)		(52)		(274
Total Corporate		(1,481)		(2,767)		(3,631)		(6,729
Operating loss		(263)		(6,949)		(5,515)		(13,331
Interest expense, net		72		1,047		199		2,154
Other, net		(93)		(154)		(212)		(247
Loss from continuing operations before income taxes		(242)		(7,842)		(5,502)		(15,238
Income tax benefit		(44)		(1,693)		(1,210)		(3,301
Loss from continuing operations		(198)		(6,149)		(4,292)		(11,937
Loss from discontinued operations, net of tax		(728)		(8,487)		(2,127)		(7,898
Net loss	\$	(926)	\$	(14,636)	\$	(6,419)	\$	(19,835
Net loss per common share from continuing operations								
Basic	\$	(0.02)	¢	(0.60)	¢	(0.42)	·	(1.18
Diluted	\$	(0.02)		(0.60)		(0.42)		(1.18
Diuce	φ	(0.02)	Ф	(0.00)	φ	(0.42)	φ	(1.10
Net loss per common share from discontinued operations								
Basic	\$	(0.07)	\$	(0.84)	\$	(0.21)	\$	(0.77
Diluted	\$	(0.07)	\$	(0.84)	\$	(0.21)	\$	(0.77
Net loss per common share								
Basic	\$	(0.09)	\$	(1.44)	\$	(0.63)	\$	(1.95
Diluted	\$	(0.09)	\$	(1.44)	\$	(0.63)	\$	(1.95
Average shares outstanding								
Basic		10,126		10,170		10,110		10,159
Diluted		10,126		10,170		10,110		10,159
Other data:								
Adjusted EBITDA <sup>1</sup>	\$	2,112	\$	(4,754)	\$	(1,003)	\$	(8,489
1								

<sup>&</sup>lt;sup>1</sup>The term Adjusted EBITDA is a non-GAAP financial measure that the Company believes is useful to investors in evaluating its results to determine the value of a company. An item is excluded in the measure if its periodic value is inconsistent and sufficiently material that not identifying the item would render period comparability less meaningful to the reader or if including the item provides a clearer representation of normalized periodic earnings. The Company excludes in Adjusted EBITDA two categories of items: 1) Base EBITDA components, including: interest expense, income taxes, depreciation and amortization, and 2) Material transaction costs including: goodwill impairment, asset impairment, gain on lease modification, stock-based compensation, non-cash lease cost, acquisition costs and other fees, retention costs and restructuring & severance costs from net income. For a reconciliation of this non-GAAP measure to the most comparable GAAP equivalent, refer to the Reconciliation of Net Income (Loss) to Adjusted EBITDA.

		Six Months En	ne 30,	
		2024		2023
Operating activities				
Net loss	\$	(6,419)	\$	(19,835)
Loss from discontinued operations, net of tax		(2,127)		(7,898)
Net loss from continuing operations		(4,292)		(11,937)
Adjustments to reconcile net loss to net cash provided by operating activities:				
Depreciation expense		3,051		3,112
Amortization expense		744		752
Amortization of debt issuance costs		50		50
Deferred income taxes		(1,210)		(5,515)
Provision for losses on accounts receivable		264		32
Provision for losses on inventories		906		1,194
Loss on disposal of property, plant and equipment		_		182
Non-cash lease expense		111		126
Stock-based compensation expense		368		404
Changes in operating assets and liabilities:				
Accounts receivable		(3,813)		2,286
Inventories		5,483		16,086
Other assets and liabilities		(907)		(251)
Accounts payable		202		4,780
Accrued expenses		1,364		(402)
Accrued income taxes		630		(743)
Net cash provided by operating activities - continuing operations	·	2,951		10,156
Net cash (used in) provided by operating activities - discontinued operations		(521)		7,916
Net cash provided by operating activities		2,430		18,072
Investing activities				
Purchases of property, plant and equipment		(770)		(1,235)
Net cash used in investing activities - continuing operations		(770)		(1,235)
Net cash used in investing activities - discontinued operations				(390)
Net cash used in investing activities		(770)		(1,625)
Financing activities		(* * * )		( 9 7
Borrowings from long-term debt		107,700		139,137
Proceeds from note payable		914		900
Payments on long-term debt		(107,700)		(156,166)
Payments on note payable		(359)		(387)
Principal payments on finance lease obligations		(151)		(151)
Repurchase of common stock		(320)		(504)
Net cash provided by (used in) financing activities		84		(17,171)
Increase (decrease) in cash and cash equivalents		1.744		(724)
Less: Cash and cash equivalents of discontinued operations		1,/44		1
Cash and cash equivalents of discontinued operations  Cash and cash equivalents, beginning of period		1,851		1,440
. , , , , , , , , , , , , , , , , , , ,	\$	3,595	\$	717
Cash and cash equivalents, end of period	<b>y</b>	3,393	φ	/1/

Considitated         Book los from continuing operations         \$ (6,149)         \$ (4,292)         \$ (1,1937)         Adjustments         Total contents of the continuing operations         \$ (6,149)         \$ (4,292)         \$ (1,1937)         Adjustments         \$ (1,1937)         Adjustments         \$ (1,1937)         \$ (1,1937)         \$ (2,104)         \$ (2,104)         \$ (2,104)         \$ (2,104)         \$ (2,104)         \$ (2,104)         \$ (2,104)         \$ (2,104)         \$ (2,104)         \$ (2,104)         \$ (2,104)         \$ (2,104)         \$ (2,104)         \$ (2,104)         \$ (2,104)         \$ (2,104)         \$ (2,104)         \$ (2,104)         \$ (2,104)         \$ (2,104)         \$ (2,104)         \$ (2,104)         \$ (2,104)         \$ (2,104)         \$ (2,104)         \$ (2,104)         \$ (2,104)         \$ (2,104)         \$ (2,104)         \$ (2,104)         \$ (2,104)         \$ (2,104)         \$ (2,104)         \$ (2,104)         \$ (2,104)         \$ (2,104)         \$ (2,104)         \$ (2,104)         \$ (2,104)         \$ (2,104)         \$ (2,104)         \$ (2,104)         \$ (2,104)         \$ (2,104)         \$ (2,104)         \$ (2,104)         \$ (2,104)         \$ (2,104)         \$ (2,104)         \$ (2,104)         \$ (2,104)         \$ (2,104)         \$ (2,104)         \$ (2,104)         \$ (2,104)         \$ (2,104)         \$ (2,104)         \$ (2,		Three Months Ended June 30,					Six Months Ended June 30,				
Net loss from continuing operations         \$ (98)         (6,149)         (4,202)         (1,1937)           Adjustments         Tenterest ceptes         72         1,047         1,99         2,154           Income taxes         (1,431)         1,563         3,015         3,112           Amortization         377         376         7,41         752           EBITIDA         1,738         (4,856)         (1,508)         (2,220)           Acquisition costs and other         6         7         6         9         2,77           Non-scall lease expense         5         63         111         126           Retention expense         2         1,72         2,63         111         126           Retention expense         5         2,12         2,479         2,03         1         1         1         2           Adjusted EBITDA         5         2,12         2,479         2,03         3         1         1         2         2         3         1         1         2         2         3         3         3         3         3         3         3         3         3         3         3         3         3         3 <th>(\$ in thousands)</th> <th> 2024</th> <th></th> <th>2023</th> <th></th> <th>2024</th> <th></th> <th>2023</th>	(\$ in thousands)	 2024		2023		2024		2023			
Adjustments         72         1,047         199         2,154           Interest expense         (44)         (1,693)         (1,210)         (3,301)           Depreciation         1,531         1,563         3,511         3,512           Amortization         1,738         (4,855)         1,508         2,729           EBITDA         1,738         (4,855)         (1,608)         2,220           Acquisition costs and other         6         7         16         79         278           Shock-based compensation         44         16         104         223           None-cash lease expenses         5         6         111         126           Restructuring and severance cost         2         2         0,47         2.08         9           Agusted EBITDA         \$2,08         7         2.08         9           Agusted EBITDA         \$2,012         \$4,75         \$2,00         \$3,80           Agusted EBITDA         \$2,02         \$4,80         \$1,00         \$2,20           Vesiculty Certain         \$2,00         \$2,80         \$2,20           Vesiculty Certain         \$2,00         \$2,80         \$2,20           Vesiculty Certain	Consolidated										
Interest expense         72         1.04         1.99         2,154           Income taxes         (44)         (1,693)         (2,101)         3.301         3.101         3.101         3.101         3.101         3.101         3.101         3.101         3.101         3.101         3.101         3.101         3.101         3.101         3.101         3.101         3.101         3.101         3.101         3.101         3.101         3.101         3.101         3.101         3.101         3.101         3.101         3.101         3.101         3.101         3.101         3.101         3.101         3.101         3.101         3.101         3.101         3.101         3.101         3.101         3.101         3.101         3.101         3.101         3.101         3.101         3.101         3.101         3.101         3.101         3.101         3.101         3.101         3.101         3.101         3.101         3.101         3.101         3.101         3.101         3.101         3.101         3.101         3.101         3.101         3.101         3.101         3.101         3.101         3.101         3.101         3.101         3.101         3.101         3.101         3.101         3.101         3.101	Net loss from continuing operations	\$ (198)	\$	(6,149)	\$	(4,292)	\$	(11,937)			
Incentacis         (44)         (1,03)         (1,20)         (3,30)           Depreciation         1,531         3,76         3,74         752           EBITDA         1,738         (4856)         (1,508)         (2,20)           Acquisition costs and other         67         16         79         2,270           Schebased compensation         44         16         104         237           Non-cash lease expenses         5         63         111         126           Restricting and sevenaceosts         20         7         3         7           Restricting and sevenaceosts         20         7         20         9         9           Aguisted EBITDA         2112         2 (475)         2 (100)         2 (848)         8         9         9         18         3         1         1 (848)         1 (848)         1 (848)         1 (848)         1 (848)         1 (848)         1 (848)         1 (848)         2 (848)         2 (848)         2 (848)         3         3         1 (848)         3         3         1 (848)         3         3         1 (848)         3         3         1 (848)         3         3         3         2 (848)         3	Adjustments:										
Depreciation         1,531         1,563         3,01         3,112           Amoritation         377         376         748         752           EBITIDA         1,738         (4,856)         1,508         9,220           Acquisition costs and other         67         16         79         277           Non-scale lease expense         44         16         10         223           Restructuring and severance costs         208         7         208         11         126           Restructuring and severance costs         208         7         208         9         13           Adjusted EBITDA         \$ 2,012         9,049         1,010         \$ 8,089           Verification         \$ 40         9,049         1,010         \$ 8,089           Verification         \$ 40         9,049         1,010         \$ 8,089           Verification (closs)         \$ 40         9,049         \$ 1,00         \$ 2,00           Verification (closs)         \$ 20         1,88         39         1,1         \$ 1,00           Amoritation expense         964         9,56         1,918         1,90         \$ 1,00         \$ 1,00         \$ 1,00         \$ 1,00         \$ 1,00	Interest expense	72		1,047		199		2,154			
Amortization         377         376         744         752           BBTDA         1,788         (4,856)         1,089         9,290           Stock-based compensation         68         16         79         277           Stock-based compensation         44         16         104         237           Non-sach seek sepense         5         6         3         11         18           Restructuring and severance costs         2         4         7         20         8         9           Agusted EBITDA         2         2,1212         4,0454         9         10,100         8,048           Agusted Compensation         3         2         1,000         1,010         8         1,010         1,010         1,010         1,010         1,010         1,010         1,010         1,010         1,010         1,010         1,010         1,010         1,010         1,010         1,010         1,010         1,010         1,010         1,010         1,010         1,010         1,010         1,010         1,010         1,010         1,010         1,010         1,010         1,010         1,010         1,010         1,010         1,01         1,010         1,010	Income taxes	(44)		(1,693)		(1,210)		(3,301)			
EBITDA         1,738         (4,856)         (1,508)         (9,200)           Acquisition costs and other         67         16         79         277           Non-cash lease expense         55         63         111         126           Restructuring and severance costs         208         7         208         91           Adjusted EBITDA         \$ 2,112         (4,754)         \$ 1,003         8,8489           Vesically Chemicals         \$ 208         7         208         91           Adjusted EBITDA         \$ 2,012         (4,754)         \$ 1,003         8,8489           Vesically Chemicals         \$ 208         \$ 1,003         \$ 8,849           Vesical Chemicals         \$ 409         \$ 818         \$ 1,003         \$ 8,859           Veliastine         \$ 409         \$ 818         \$ 1,003         \$ 5,23           Veliastine         \$ 409         \$ 818         \$ 1,009         \$ 5,23           Veliastine         \$ 409         \$ 818         \$ 3         \$ 3           Depreciation expense         \$ 96         \$ 95         \$ 1,918         \$ 1,908           EBITDA         \$ 1,572         \$ 31         \$ 1,252         \$ 2,799           Acquisition exp	Depreciation	1,531		1,563		3,051		3,112			
Acquisition costs and other         67         16         79         277           Stock-based compensation         44         16         104         237           Non-eash lease expense         55         63         111         126           Retincturing and severance costs         208         9         8         9           Adjusted EBITDA         \$ 2,112         \$ (4,754)         \$ (1,003)         \$ (8,88)           Specialty Chemicals         ***         ***         \$ (4,754)         \$ (1,003)         \$ (8,88)           Vet income (loss)         \$ 40         \$ (8)         \$ (1,003)         \$ (8,88)         \$ (1,003)         \$ (8,88)           Vet income (loss)         \$ 40         \$ (8)         \$ (1,003)         \$ (8,88)         \$ (1,003)         \$ (8,88)         \$ (1,003)         \$ (8,88)         \$ (1,003)         \$ (8,88)         \$ (1,003)         \$ (8,88)         \$ (1,003)         \$ (8,88)         \$ (1,003)         \$ (1,003)         \$ (8,88)         \$ (1,004)         \$ (1,003)         \$ (1,003)         \$ (1,003)         \$ (1,003)         \$ (1,003)         \$ (1,003)         \$ (1,003)         \$ (1,003)         \$ (1,003)         \$ (1,003)         \$ (1,003)         \$ (1,003)         \$ (1,003)         \$ (1,003)         \$ (1,003)         <	Amortization	377		376		744		752			
Stock-based compensation         44         16         104         2.37           Non-cash lease expense         5         63         111         1.26           Restructuring and severance costs         208         7         208         9.1           Adjusted EBITDA         \$ 2,112         \$ (47.54)         \$ (1,003)         \$ (8.88)           Veg slage         4.2 %         9.4%         \$ (1,003)         \$ (8.88)           Veg slage         3         4.2 %         9.4%         \$ (1,003)         \$ (8.88)           Veg slage         3         4.2 %         9.4%         \$ (1,003)         \$ (8.88)           Veg slage         8         4.9         \$ (8.88)         \$ (1,004)         \$ (8.88)           Veg slage         8         4.9         \$ (8.88)         \$ (1,004)         \$ (8.88)         \$ (1,004)         \$ (8.88)         \$ (1,004)         \$ (8.88)         \$ (1,004)         \$ (8.88)         \$ (1,004)         \$ (1,004)         \$ (1,004)         \$ (1,004)         \$ (1,004)         \$ (1,004)         \$ (1,004)         \$ (1,004)         \$ (1,004)         \$ (1,004)         \$ (1,004)         \$ (1,004)         \$ (1,004)         \$ (1,004)         \$ (1,004)         \$ (1,004)         \$ (1,004)         \$ (1,004)         \$ (	EBITDA	1,738		(4,856)		(1,508)		(9,220)			
Non-cash lease expense         55         63         111         126           Retention expense         —         —         3         —           Restructuring and severance costs         208         7         208         9           Adjusted EBITDA         \$ 2,112         \$ (4,754)         \$ (1,003)         \$ (8,489)           % sales         \$ 2,112         \$ (4,754)         \$ (1,003)         \$ (8,489)           % sales         \$ 409         \$ (818)         \$ (1,049)         \$ 523           Specialty Chemicals         ***         ***         \$ 20         \$ (818)         \$ (1,049)         \$ 523           Adjustments         ***         ***         ***         \$ 19         \$ 18         39         31           Depreciation expense         20         \$ (818)         \$ (1,049)         \$ 523         ***           Adjustments         ***         ***         9 56         \$ 1,918         \$ 1,908           Amortization expense         20         \$ 18         \$ 348         317         \$ (16)           BEITDA         \$ 1,572         314         \$ 1,256         2,779         \$ (16)         \$ (16)         \$ (16)         \$ (16)         \$ (16)         \$ (16) <t< td=""><td>Acquisition costs and other</td><td>67</td><td></td><td>16</td><td></td><td>79</td><td></td><td>277</td></t<>	Acquisition costs and other	67		16		79		277			
Retention expense         —         —         3         —           Restructuring and severance costs         208         7         208         91           Adjusted EBITDA         22,112         14,754         10,103         8,68,489           % sales         42.2         69.4%         10,103         8,68,489           Secicity Chemicals         8         40.9         8         81.8         10,009         \$ 5.23           Velicity Chemicals         8         40.9         8         (81.8)         10,009         \$ 5.23           Velicity Chemicals         8         40.9         8         (81.8)         10,009         \$ 5.23           Velicity Chemicals         8         20         18         3.9         3.1         10,009         \$ 1.8         3.9         3.1         10,009         \$ 1.0         \$ 1.0         \$ 1.0         \$ 1.0         \$ 1.0         \$ 1.0         \$ 1.0         \$ 1.0         \$ 1.0         \$ 1.0         \$ 1.0         \$ 1.0         \$ 1.0         \$ 1.0         \$ 1.0         \$ 1.0         \$ 1.0         \$ 1.0         \$ 1.0         \$ 1.0         \$ 1.0         \$ 1.0         \$ 1.0         \$ 1.0         \$ 1.0         \$ 1.0         \$ 1.0         \$ 1.0	Stock-based compensation	44		16		104		237			
Restricturing and severance costs         208         7         208         9           Adjuste EBITDA         \$ 2,112         \$ (4,754)         \$ (1,003)         \$ (8,489)           % sales         2 2,000         \$ (3,000)         \$ (1,000)         \$ (8,18)           Specialty Chemicals         \$ 400         \$ (818)         \$ (1,049)         \$ 523           Adjustems:         \$ 20         18         3.9         \$ 1,000           Interest expense         964         956         1,918         1,908           Amonization expense         197         158         348         317           Aprenance oxition expense         19         22         31         1,25         2,779           Aprenance oxition expense         19         2         3         1,46         3         1,410         3         1,41         2         1,41         2	Non-cash lease expense	55		63		111		126			
Adjusted EBITDA         S         2,112         S         4,754         \$1,003         \$1,8489           % sales         42.%         0,43%         0,43%         1,10%         \$1,818           Specialty Chemicals         Secialty Chemicals           Net income (loss)         \$40         \$1,818         \$1,90         \$2,23           Adjustments         Secialty Chemicals           Interest expense         20         18         39         31           Depreciation expense         964         956         1,918         1,908           Amortization expense         964         956         1,918         1,908           BEITDA         1,572         314         1,256         2,779           Acquisition costs and other         1         2         31         1,256         2,779           Acquisition expense         19         2         38         46           Non-eath lease expense         19         2         38         46           Restructuring and severance costs         19         2         38         46           Restructuring and severance costs         889         3,303         6(3)         6(5)           Volutian Products	Retention expense	_		_		3		_			
Specialty Chemicals         4.2 %         (9.4)%         (1.1)%         (8.1)           Specialty Chemicals         Specialty Chemicals           Net income (loss)         \$ 409         \$ (818)         (1.049)         \$ 523           Adjustmens:         The preciation expense         20         18         39         31           Depreciation expense         964         956         1,918         1,908           Amortization expense         964         956         1,918         1,908           Amortization expense         964         956         1,918         1,908           Amortization expense         169         158         348         317           EBITDA	Restructuring and severance costs	208		7		208		91			
Specialty Chemicals         S         409         S         (818)         S         (1,049)         S         523           Adjustments:         Interest expense         20         18         39         31           Depreciation expense         964         956         1,918         1,908           Amortization expense         179         158         348         317           EBITDA         1,722         314         1,256         2,779           Acquisition costs and other         -         -         -         -         2         2         38         446           Non-cash lease expense         199         22         38         46           Restructuring and severance costs         109         -         -         -         -         -         -         -         -         -         -         -         -         -         -         -         -         -         -         -         -         -         -         -         -         -         -         -         -         -         -         -         -         -         -         -         -         -         -         -         -         - <td>Adjusted EBITDA</td> <td>\$ 2,112</td> <td>\$</td> <td>(4,754)</td> <td>\$</td> <td>(1,003)</td> <td>\$</td> <td>(8,489)</td>	Adjusted EBITDA	\$ 2,112	\$	(4,754)	\$	(1,003)	\$	(8,489)			
Note income (loss)   \$ 409	% sales	4.2 %		(9.4)%		(1.1)%		(8.1)%			
Adjustments:	Specialty Chemicals										
Interest expense   20   18   39   31     Depreciation expense   964   956   1,918   1,908     Amortization expense   179   158   348   317     Amortization expense   1,572   314   1,256   2,779     Acquisition costs and other   -     -                   Acquisition costs and other   -                                 Non-cash lease expense   19   22   38   46     Non-cash lease expense   19   22   38   46     Restructuring and severance costs   109     -	Net income (loss)	\$ 409	\$	(818)	\$	(1,049)	\$	523			
Depreciation expense   964   956   1,918   1,908   Amortization expense   179   158   348   317   2117DA   1,520   314   1,256   2,779   2,279   2,279   2,279   2,279   2,279   2,279   2,279   2,279   2,279   2,279   2,279   2,279   2,279   2,279   2,279   2,279   2,279   2,279   2,279   2,279   2,279   2,279   2,279   2,279   2,279   2,279   2,279   2,279   2,279   2,279   2,279   2,279   2,279   2,279   2,279   2,279   2,279   2,279   2,279   2,279   2,279   2,279   2,279   2,279   2,279   2,279   2,279   2,279   2,279   2,279   2,279   2,279   2,279   2,279   2,279   2,279   2,279   2,279   2,279   2,279   2,279   2,279   2,279   2,279   2,279   2,279   2,279   2,279   2,279   2,279   2,279   2,279   2,279   2,279   2,279   2,279   2,279   2,279   2,279   2,279   2,279   2,279   2,279   2,279   2,279   2,279   2,279   2,279   2,279   2,279   2,279   2,279   2,279   2,279   2,279   2,279   2,279   2,279   2,279   2,279   2,279   2,279   2,279   2,279   2,279   2,279   2,279   2,279   2,279   2,279   2,279   2,279   2,279   2,279   2,279   2,279   2,279   2,279   2,279   2,279   2,279   2,279   2,279   2,279   2,279   2,279   2,279   2,279   2,279   2,279   2,279   2,279   2,279   2,279   2,279   2,279   2,279   2,279   2,279   2,279   2,279   2,279   2,279   2,279   2,279   2,279   2,279   2,279   2,279   2,279   2,279   2,279   2,279   2,279   2,279   2,279   2,279   2,279   2,279   2,279   2,279   2,279   2,279   2,279   2,279   2,279   2,279   2,279   2,279   2,279   2,279   2,279   2,279   2,279   2,279   2,279   2,279   2,279   2,279   2,279   2,279   2,279   2,279   2,279   2,279   2,279   2,279   2,279   2,279   2,279   2,279   2,279   2,279   2,279   2,279   2,279   2,279   2,279   2,279   2,279   2,279   2,279   2,279   2,279   2,279   2,279   2,279   2,279   2,279   2,279   2,279   2,279   2,279   2,279   2,279   2,279   2,279   2,279   2,279   2,279   2,279   2,279   2,279   2,279   2,279   2,279   2,279   2,279   2,279   2,279   2,279   2,279   2,279   2,279   2,279   2,279   2,279   2,279   2,2	Adjustments:										
Amortization expense         179         158         348         317           EBITDA         1,572         314         1,256         2,779           Acquisition costs and other         —         —         —         —         2           Stock-based compensation         —         —         (23)         7         (166           Non-cash lease expense         19         22         38         46           Restructuring and severance costs         109         —         109         —           Specialty Chemicals Adjusted EBITDA         \$ 1,700         \$ 313         \$ 1,410         \$ 2,811           % segment sales         \$ 1,700         \$ 1.5%         3.4%         6.2           Tubular Products           Not income (loss) from continuing operations         \$ 889         \$ (3,303)         \$ (613)         \$ (6,595)           Adjustition expense         \$ 889         \$ (3,303)         \$ (613)         \$ (6,595)           Adjustition expense         \$ 889         \$ (3,503)         \$ (613)         \$ (6,595)           Adjustition expense         \$ 1,633         (2,500)         874         (4,999)           Acquisition costs and other         \$ 1,633         (2,500)         874	•	20				39		31			
Sebitor   1,572   314   1,256   2,779     Acquisition costs and other		964		956		1,918		1,908			
Acquisition costs and other         —         —         —         —         2           Stock-based compensation         —         (23)         7         (16)           Non-cash lease expense         19         22         38         46           Restructuring and severance costs         109         —         109         —         —         Sepecialty Chemicals Adjusted EBITDA         \$ 1,700         \$ 313         \$ 1,410         \$ 2,811         \$ 2,811         \$ 3,4%         6,2         \$ 2,811         \$ 3,4%         6,2         \$ 2,811         \$ 3,303         \$ (613)         \$ (6,595)         \$ 6,295         \$ 3,303         \$ (613)         \$ (6,595)         \$ (6,595)         \$ (6,595)         \$ (6,595)         \$ (6,595)         \$ (6,595)         \$ (6,595)         \$ (6,595)         \$ (6,595)         \$ (6,595)         \$ (6,595)         \$ (6,595)         \$ (6,595)         \$ (6,595)         \$ (6,595)         \$ (6,595)         \$ (6,595)         \$ (6,595)         \$ (6,595)         \$ (6,595)         \$ (6,595)         \$ (6,595)         \$ (6,595)         \$ (6,595)         \$ (6,595)         \$ (6,595)         \$ (6,595)         \$ (6,595)         \$ (6,595)         \$ (6,595)         \$ (6,595)         \$ (6,595)         \$ (6,595)         \$ (6,595)         \$ (6,595)         \$ (6,595)	Amortization expense	 179		158		348		317			
Stock-based compensation         —         (23)         7         (16           Non-cash lease expense         19         22         38         46           Restructuring and severance costs         109         —         109         —           Specialty Chemicals Adjusted EBITDA         \$ 1,700         \$ 313         \$ 1,410         \$ 2,811           % segment sales         7,9%         1,5%         3,4%         6,2           Tubular Products           Net income (loss) from continuing operations         \$ 889         \$ (3,303)         \$ (613)         \$ (6,595)           Adjustments:         Depreciation expense         546         585         1,091         1,160           Amortization expense         198         218         396         436           EBITDA         1,633         (2,500)         874         (4,999)           Acquisition costs and other         15         —         26         —           Stock-based compensation         —         2         11         (18           Non-cash lease expense         25         31         50         61           Restructuring and severance costs         31         —         31         8           T	EBITDA	1,572		314		1,256		2,779			
Non-cash lease expense         19         22         38         46           Restructuring and severance costs         109         —         109         —           Specialty Chemicals Adjusted EBITDA         \$ 1,700         \$ 313         \$ 1,410         \$ 2,811           We segment sales         7,9%         1,5%         3,4%         6,2           Tubular Products           Net income (loss) from continuing operations         \$ 889         \$ (3,303)         \$ (613)         \$ (6,595)           Adjustments:         S         889         \$ (3,303)         \$ (613)         \$ (6,595)           Adjustments:         S         889         \$ (3,303)         \$ (613)         \$ (6,595)           Adjustments:         S         889         \$ (3,303)         \$ (613)         \$ (6,595)           Adjustments:         S         889         \$ (3,303)         \$ (613)         \$ (6,595)           Adjustments:         S         889         \$ (3,303)         \$ (613)         \$ (6,595)           Adjustments:         S         198         218         396         436           EBITDA         1,633         (2,500)         874         (4,999)           Acquisition costs and other         15	Acquisition costs and other	_		_		_		2			
Restructuring and severance costs         109         —         109         —         109         —         2,811         Sepecialty Chemicals Adjusted EBITDA         \$ 1,700         \$ 313         \$ 1,410         \$ 2,811           % segment sales         7,9 %         1,5 %         3,4 %         6,2           Tubular Products           Net income (loss) from continuing operations         \$ 889         \$ (3,303)         \$ (613)         \$ (6,595)           Adjustments:         Depreciation expense         546         585         1,091         1,160           Amortization expense         198         218         396         436           EBITDA         1,633         (2,500)         874         (4,999)           Acquisition costs and other         15         —         26         —           Stock-based compensation         —         2         11         (18           Non-cash lease expense         25         31         50         61           Restructuring and severance costs         31         —         31         84           Tubular Products Adjusted EBITDA         \$ 1,704         \$ (2,467)         \$ 992         \$ (4,872)	Stock-based compensation	_		(23)		7		(16)			
Specialty Chemicals Adjusted EBITDA         \$ 1,700         \$ 313         \$ 1,410         \$ 2,811           We segment sales         7.9 %         1.5 %         3.4 %         6.2           Tubular Products           Net income (loss) from continuing operations         \$ 889         \$ (3,303)         \$ (613)         \$ (6,595)           Adjustments:         Depreciation expense         546         585         1,091         1,160           Amortization expense         198         218         396         436           EBITDA         1,633         (2,500)         874         (4,999)           Acquisition costs and other         15         —         26         —           Stock-based compensation         —         2         11         (18           Non-cash lease expense         25         31         50         61           Restructuring and severance costs         31         —         31         84           Tubular Products Adjusted EBITDA         \$ 1,704         \$ (2,467)         \$ 992         \$ (4,872)	Non-cash lease expense	19		22		38		46			
We segment sales         7.9 %         1.5 %         3.4 %         6.2           Tubular Products           Net income (loss) from continuing operations         \$ 889 \$ (3,303) \$ (613) \$ (6,595)           Adjustments:         Depreciation expense           Depreciation expense         546 \$ 585 \$ 1,091 \$ 1,160           Amortization expense         198 \$ 218 \$ 396 \$ 436           EBITDA         1,633 \$ (2,500) \$ 874 \$ (4,999)           Acquisition costs and other         15 \$ 26 \$           Stock-based compensation         2 \$ 11 \$ (18)           Non-cash lease expense         25 \$ 31 \$ 50 \$ 61           Restructuring and severance costs         31 \$ 31 \$ 84           Tubular Products Adjusted EBITDA         \$ 1,704 \$ (2,467) \$ 992 \$ (4,872)	Restructuring and severance costs	 109		_		109		_			
Tubular Products       Net income (loss) from continuing operations     \$ 889     \$ (3,303)     \$ (613)     \$ (6,595)       Adjustments:       Depreciation expense     546     585     1,091     1,160       Amortization expense     198     218     396     436       EBITDA     1,633     (2,500)     874     (4,999)       Acquisition costs and other     15     —     26     —       Stock-based compensation     —     2     11     (18       Non-cash lease expense     25     31     50     61       Restructuring and severance costs     31     —     31     84       Tubular Products Adjusted EBITDA     \$ 1,704     \$ (2,467)     \$ 992     \$ (4,872)	Specialty Chemicals Adjusted EBITDA	\$ 1,700	\$	313	\$	1,410	\$	2,811			
Net income (loss) from continuing operations     \$ 889     \$ (3,303)     \$ (613)     \$ (6,595)       Adjustments:       Depreciation expense     546     585     1,091     1,160       Amortization expense     198     218     396     436       EBITDA     1,633     (2,500)     874     (4,999)       Acquisition costs and other     15     —     26     —       Stock-based compensation     —     2     11     (18       Non-cash lease expense     25     31     50     61       Restructuring and severance costs     31     —     31     84       Tubular Products Adjusted EBITDA     \$ 1,704     \$ (2,467)     \$ 992     \$ (4,872)	% segment sales	 7.9 %		1.5 %		3.4 %		6.2 %			
Adjustments:       Depreciation expense     546     585     1,091     1,160       Amortization expense     198     218     396     436       EBITDA     1,633     (2,500)     874     (4,999)       Acquisition costs and other     15     —     26     —       Stock-based compensation     —     2     11     (18)       Non-cash lease expense     25     31     50     61       Restructuring and severance costs     31     —     31     84       Tubular Products Adjusted EBITDA     \$ 1,704     \$ (2,467)     \$ 992     \$ (4,872)	Tubular Products										
Depreciation expense         546         585         1,091         1,160           Amortization expense         198         218         396         436           EBITDA         1,633         (2,500)         874         (4,999)           Acquisition costs and other         15         —         26         —           Stock-based compensation         —         2         11         (18           Non-cash lease expense         25         31         50         61           Restructuring and severance costs         31         —         31         84           Tubular Products Adjusted EBITDA         \$ 1,704         \$ (2,467)         \$ 992         \$ (4,872)	Net income (loss) from continuing operations	\$ 889	\$	(3,303)	\$	(613)	\$	(6,595)			
Amortization expense         198         218         396         436           EBITDA         1,633         (2,500)         874         (4,999)           Acquisition costs and other         15         —         26         —           Stock-based compensation         —         2         11         (18           Non-cash lease expense         25         31         50         61           Restructuring and severance costs         31         —         31         84           Tubular Products Adjusted EBITDA         \$ 1,704         \$ (2,467)         \$ 992         \$ (4,872)	Adjustments:										
EBITDA         1,633         (2,500)         874         (4,999)           Acquisition costs and other         15         —         26         —           Stock-based compensation         —         2         11         (18           Non-cash lease expense         25         31         50         61           Restructuring and severance costs         31         —         31         84           Tubular Products Adjusted EBITDA         \$ 1,704         \$ (2,467)         \$ 992         \$ (4,872)	Depreciation expense	546		585		1,091		1,160			
Acquisition costs and other       15       —       26       —         Stock-based compensation       —       2       11       (18         Non-cash lease expense       25       31       50       61         Restructuring and severance costs       31       —       31       84         Tubular Products Adjusted EBITDA       \$ 1,704       \$ (2,467)       \$ 992       \$ (4,872)	Amortization expense	198		218		396		436			
Stock-based compensation         —         2         11         (18)           Non-cash lease expense         25         31         50         61           Restructuring and severance costs         31         —         31         84           Tubular Products Adjusted EBITDA         \$ 1,704         \$ (2,467)         \$ 992         \$ (4,872)	EBITDA	1,633		(2,500)		874		(4,999)			
Non-cash lease expense         25         31         50         61           Restructuring and severance costs         31         —         31         84           Tubular Products Adjusted EBITDA         \$ 1,704         \$ (2,467)         \$ 992         \$ (4,872)	Acquisition costs and other	15				26					
Restructuring and severance costs         31         —         31         84           Tubular Products Adjusted EBITDA         \$ 1,704         \$ (2,467)         \$ 992         \$ (4,872)	Stock-based compensation	_		2		11		(18)			
Restructuring and severance costs         31         —         31         84           Tubular Products Adjusted EBITDA         \$ 1,704         \$ (2,467)         \$ 992         \$ (4,872)	•	25		31		50		61			
· · · · · · · · · · · · · · · · · · ·	-	31		_		31		84			
% segment sales 5.9 % (8.5)% 1.9 % (8.1)	Tubular Products Adjusted EBITDA	\$ 1,704	\$	(2,467)	\$	992	\$	(4,872)			
	% segment sales	5.9 %		(8.5)%		1.9 %		(8.1)%			